This site uses cookies. By using this site you agree to receiving cookies. View Policy.

133%
Raised
£355,430
Investors
538
Target
£267,000
Equity
2.59%
Pre-money valuation
£13,350,000

Focusing on a $651m market, growing due to increased life expectancy and diseases related to ageing, REGEMAT 3D develops biofabrication devices to create tissues and organs, accelerating research in the laboratory. With 2019 sales of c. €682,9k, their devices are now being used in >25 countries.

  • The bioprinting market is estimated to be worth approx $1.6bn by 2024
  • Developed proprietary technology, based on bioprinting and bioreactors
  • Customers in more than 25 countries
  • Led by a multidisciplinary team of entrepreneurs, scientists and executives

Idea

Research on cells and biomaterials to better understand the behaviour of living tissues and being able to regenerate them has traditionally been done using mainly 2D cultures. Our Bioprinters and Bioreactors are giving researchers access to use 3D printing with biomaterials and cells that are able to mirror the structure of living tissue.

Since launching in 2015, we have sold to more than 100 research institutions and pharma companies around the world. This technology ultimately aims to create functional tissues and living organs in the lab that can be transplanted to patients.

Our current global client base includes University Hospital of Basel (Switzerland), Florida Institute of Technology (USA), University of Western Australia and l'Université libre de Bruxelles, ULB.

Last year we turned over sales of c. €682,9k (EBITDA +€85,885.27), and have recently launched a new bioprinter called REG4Life, a new line of Bioreactors (BMAP) and a department to provide our customers with the bioinks and consumables needed for their research.

We believe this is a market that will grow significantly in the coming years and that is why we are raising now to finance our expansion and increase our sales force and marketing, as well as producing more scientific data on the different tissue applications and improving our manufacturing capabilities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the REGEMAT 3D pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

This pitch is approved by Crowdcube

This pitch is approved as a financial promotion by Crowdcube Capital Limited. Every pitch on Crowdcube is reviewed to ensure it is fair, clear and not misleading.

As part of our commitment to investor transparency, Crowdcube’s Due Diligence Charter outlines the analysis and verification that is conducted on equity fundraises on Crowdcube by our legal and compliance professionals.

Read more

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.